Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17409968 | 1.00 | SLC6A2 (0.39) | SLC6A2SSTR4MEN1KMT2AHTR1A | |
| SCHEMBL627761 | 1.00 | SLC6A2 (0.39) | SLC6A2SSTR4MEN1KMT2AHTR1A | |
| Hydrochloric Acid SCHEMBL22612729 | 0.98 | SLC6A2 (0.38) | SLC6A2SSTR4MEN1KMT2AHTR1A | |
| SCHEMBL25146515 | 0.86 | SLC6A2 (0.31) | SLC6A2SSTR4 | |
| SCHEMBL12504907 | 0.86 | SLC6A2 (0.39) | SLC6A2SSTR4MEN1KMT2AHTR1A | |
| SCHEMBL18604222 | 0.82 | SLC6A2 (0.44) | SLC6A2SSTR4 | |
| SCHEMBL1992859 | 0.82 | SLC6A2 (0.37) | SLC6A2SSTR4 | |
| SCHEMBL23089434 | 0.82 | SLC6A2 (0.44) | SLC6A2SSTR4 | |
| SCHEMBL22487983 | 0.82 | SLC6A2 (0.37) | SLC6A2SSTR4HTR1A | |
| SCHEMBL4201451 | 0.82 | SLC6A2 (0.37) | SLC6A2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-20170267696-A1 | CERTAIN PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | SLC6A2 3927/4885SSTR4 4251/4885MEN1 1294/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | SLC6A2 4742/4885SSTR4 4660/4885MEN1 4080/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | SLC6A2 4742/4885SSTR4 4660/4885MEN1 4080/4885 |
| US-20170267696-A1 | CERTAIN PROTEIN KINASE INHIBITORS | CDK4, CDK6, CDK2 | SLC6A2 4854/4885SSTR4 4352/4885MEN1 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.